Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.

Lionetti R, Piccolo P, Lenci I, Siciliano M, Visco-Comandini U, De Santis A, Pompili M, Milana M, Taibi C, Dell'Isola S, Montalbano M, Mastroianni C, Begini P, Garbuglia AR, Angelico M, D'Offizi G.

Ann Hepatol. 2019 May - Jun;18(3):434-438. doi: 10.1016/j.aohep.2018.09.005. Epub 2019 Apr 15.

2.

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.

Pellicelli A, Messina V, Giannelli V, Distefano M, Palitti VP, Vignally P, Tarquini P, Izzi A, Moretti A, Babudieri S, Dell'Isola S, Marignani M, Scifo G, Iovinella V, Cariti G, Pompili M, Candilo FD, Fontanella L, Ettorre GM, Vennarecci G, Ippolito AM, Barbarini G; Working Group CLEO.

Gut Liver. 2019 Aug 14. doi: 10.5009/gnl18269. [Epub ahead of print]

3.

Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy.

Pontali E, Fiore V, Ialungo AM, Ranieri R, Mollaretti O, Barbarini G, Marri D, Prestileo T, Dell'Isola S, Rastrelli E, Leo G, Starnini G, Babudieri S, Madeddu G; Gruppo Infettivologi Penitenziari.

Int J Drug Policy. 2018 Sep;59:50-53. doi: 10.1016/j.drugpo.2018.06.017. Epub 2018 Jul 6.

PMID:
29986272
4.

Hospital admissions for HIV-infected prisoners in Italy.

Pontali E, Ranieri R, Rastrelli E, Iannece MD, Ialungo AM, Dell'Isola S, Liberti A, Rosario P, Casati R, Starnini G, Babudieri S.

Int J Prison Health. 2017 Jun 12;13(2):105-112. doi: 10.1108/IJPH-02-2016-0004.

PMID:
28581372
5.

Erratum to: Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel.

Ranieri R, Starnini G, Carbonara S, Pontali E, Leo G, Romano A, Panese S, Monarca R, Prestileo T, Barbarini G, Babudieri S; SIMSPe Group.

Infection. 2017 Apr;45(2):249. doi: 10.1007/s15010-017-0983-6. No abstract available.

PMID:
28181203
6.

A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma.

Cabibbo G, Petta S, Barbàra M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxì A, Colombo M, Cammà C; ITA.LI.CA study group.

Liver Int. 2017 Aug;37(8):1157-1166. doi: 10.1111/liv.13357. Epub 2017 Feb 1.

PMID:
28061016
7.

Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel.

Ranieri R, Starnini G, Carbonara S, Pontali E, Leo G, Romano A, Panese S, Monarca R, Prestileo T, Barbarini G, Babudieri S; SIMSPe Group.

Infection. 2017 Apr;45(2):131-138. doi: 10.1007/s15010-016-0973-0. Epub 2016 Dec 26. Review. Erratum in: Infection. 2017 Apr;45(2):249.

PMID:
28025726
8.

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.

Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Tovoli F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Boccaccio V, Craxì A, Bruno S, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) Group.

Aliment Pharmacol Ther. 2017 Jan;45(1):160-168. doi: 10.1111/apt.13821. Epub 2016 Oct 28.

9.

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F; Italian LiverCancer (ITA.LI.CA) group.

Liver Int. 2017 Mar;37(3):423-433. doi: 10.1111/liv.13242. Epub 2016 Oct 2.

PMID:
27566596
10.

The evolutionary scenario of hepatocellular carcinoma in Italy: an update.

Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2017 Feb;37(2):259-270. doi: 10.1111/liv.13204. Epub 2016 Aug 17.

PMID:
27427866
11.

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.

Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group.

PLoS Med. 2016 Apr 26;13(4):e1002006. doi: 10.1371/journal.pmed.1002006. eCollection 2016 Apr.

12.

Years of life that could be saved from prevention of hepatocellular carcinoma.

Cucchetti A, Trevisani F, Bucci L, Ravaioli M, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Pinna AD; Italian Liver Cancer Group.

Aliment Pharmacol Ther. 2016 Apr;43(7):814-24. doi: 10.1111/apt.13554. Epub 2016 Feb 11.

13.

Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.

Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group.

Am J Gastroenterol. 2016 Jan;111(1):70-7. doi: 10.1038/ajg.2015.389. Epub 2016 Jan 5. Erratum in: Am J Gastroenterol. 2018 Jul;113(7):1100.

PMID:
26729544
14.

Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.

Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group.

Aliment Pharmacol Ther. 2016 Feb;43(3):385-99. doi: 10.1111/apt.13485. Epub 2015 Dec 14.

15.

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study.

Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S; HCC-NAFLD Italian Study Group.

Hepatology. 2016 Mar;63(3):827-38. doi: 10.1002/hep.28368. Epub 2016 Jan 14.

PMID:
26599351
16.

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study.

Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U; Italian Liver Cancer (ITA.LI.CA) group.

J Hepatol. 2015 Mar;62(3):617-24. doi: 10.1016/j.jhep.2014.10.037. Epub 2014 Oct 30.

PMID:
25450706
17.

Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.

Sacco R, Mismas V, Granito A, Musettini G, Masi G, Caparello C, Vivaldi C, Felder M, Bresci G, Fornaro L; Italian Liver Cancer (IT.LI.CA) group.

Int J Biol Markers. 2015 Feb 24;30(1):e65-72. doi: 10.5301/jbm.5000117.

PMID:
25450648
18.

Prognosis of untreated hepatocellular carcinoma.

Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Hepatology. 2015 Jan;61(1):184-90. doi: 10.1002/hep.27443. Epub 2014 Nov 26.

PMID:
25234419
19.

Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma.

Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Giannini EG, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Bernardi M, Pinna AD; Italian Liver Cancer Group.

J Hepatol. 2014 Aug;61(2):333-41. doi: 10.1016/j.jhep.2014.03.037. Epub 2014 Apr 6.

PMID:
24717522
20.

Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis.

Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group.

Clin Gastroenterol Hepatol. 2014 Nov;12(11):1927-33.e2. doi: 10.1016/j.cgh.2014.02.025. Epub 2014 Feb 26.

PMID:
24582947

Supplemental Content

Loading ...
Support Center